Saturday, October 31, 2026
ExploreSearch
Via News
MarketCommodities

Crude Oil Futures Went Down By Over 8% In The Last 10 Sessions

ViaNews Editorial Team

October 31, 2023

Crude Oil Futures Went Down By Over 8% In The Last 10 Sessions

(VIANEWS) - Crude Oil (CL) has been up by 8.17% for the last 10 sessions. At 02:51 EST on Tuesday, 31 October, Crude Oil (CL) is $82.98.

Volume

Today's last reported volume for Crude Oil is 20716, 99.99% below its average volume of 15464540187.48.

Previous days news about Crude Oil (CL)

  • Crude oil forecast: markets continue to move on external factors - 30 October 2023. According to DailyForex on Monday, 30 October, "In the end, both WTI Crude Oil and Brent markets find themselves at critical junctures, with future directions hinging on their ability to navigate key resistance and support levels, as well as their response to geopolitical events and global risk dynamics. "

More news about Crude Oil (CL).

Categories

MarketCommodities

Tags

CLCommodityCommoditiesFuturesCrude OilPrice DownCommodities Price DownCommodities Now
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com